Recent research reveals a significant drop in human sperm counts, with global levels decreasing by an average of 1.2% annually since 1973, falling from 104 million to 49 million per milliliter by 2019. Alarmingly, this decline has accelerated, with sperm counts plummeting by more than 2.6% per year since 2020. While the exact causes remain uncertain, emerging studies suggest microplastics and their endocrine-disrupting chemicals may play a crucial role.
“Lower sperm counts may affect the ability to conceive,” stated René Frydman, Professor at Foch Hospital in Suresnes, France. “Historically, treatments have focused on women, yet reduced sperm count and quality are major factors in as many as half of infertility cases.”
Infertility affects up to 186 million individuals globally, with approximately 48 million couples seeking medical assistance. For over five decades, physicians have relied on Follicle-Stimulating Hormone (FSH) injections to treat infertility.
“FSH is effective in some cases, but it’s not a complete solution. Women undergoing FSH treatment typically need four to five cycles of up to 20 injections per cycle over two years to achieve a 60-70% success rate. Additionally, FSH fails to address male infertility,” explained Frydman.
Igyxos Biotherapeutics, an innovative biopharmaceutical company specializing in infertility solutions, is developing a groundbreaking therapeutic aimed at addressing both female and male infertility. IGX12, a first-in-class monoclonal antibody (mAb), enhances the bioactivity of endogenous FSH. This new approach could reduce the number of hormonal injections required significantly. Animal studies have shown that IGX12 produces superior ovarian responses in females and increases spermatogenesis in males. It is the first new molecule patented for infertility in over 40 years. Upon regulatory approval, it will be the first and only treatment available for male infertility. IGX12 is currently undergoing a Phase 1 clinical study.
“IGX12 could treat both male and female infertility simultaneously, potentially increasing success rates and reducing the burden on women by decreasing the number of required injections and involving both partners in the treatment process,” said Marie-Christine Maurel, Ph.D., Chief Science Officer & Founder at Igyxos. “By enhancing the bioactivity of endogenous FSH, IGX12 aims to increase both sperm counts in males and ovulation in females.”
About Igyxos Biotherapeutics
Igyxos Biotherapeutics is committed to meeting the growing global need for improved infertility solutions with novel therapeutics that enhance treatment efficacy for both men and women. The company is pioneering the first monoclonal antibody-based treatment to bind and enhance the activity of gonadotropins, hormones essential for reproduction, significantly improving their effectiveness in infertility treatments. Investors in Igyxos include UI investissement, Bpifrance, and Go Capital.
Related Topics:
A 2024 Study: Microplastics in Testicles – A Factor in Male Infertility?
Unlocking Reversible Male Contraception: A Revolutionary Approach to Fertility Control
